The purpose of this report is two discuss the Pharmacodynamics, pharmacokinetics, proposed benefits, research method, results of research, and possible-nursing implications of newly approved drugs for the treatment of hypertension. These drugs include Atacand HCT and Diltiazem HCL. All newly approved drugs from the FDA are either new drugs or new formulations of older drugs. The information contained in this report was derived from various web pages and online search engines. Pharmacokinetics: Atacand HCT (Candesartan celexetil)Candesartan is quickly and completely bioactivated by hydrolysis during the absorption from the GI tract to a angiotensin II receptor antagonist (www.rxlist.com). Candesartan is excreted mainly unchanged in urine and feces through bile. Atacand’s other component is hydrochlorothiazide, which is a thiazide diuretic. Thiazide effect the renal tubular mechanisms of electrolyte reabsorption. This is done directly by increasing the excretion of sodium and chloride in equal amounts (www.centerwatch.com). Post administration Candesartan celexetil bioavailability was estimated at 15%, peak concentration was reached within 3-4 hours and inactive metabolites were not shown to accumulate upon daily dosing (www.rxlist.com). The distribution of Candesartan was reported at 0.13 l. per kilogram; in the shown to be highly bound to plasma proteins (*99%). Candesartan was not shown through laboratory testing of rats to cross the blood brain barrier, the drug was shown however through these studies to cross the placental barrier and is distributed in the fetus (www.rxlist.com). Pharmacodynamics: Atacand HCTCandesartan inhibit the effects of angiotensin II in a dose dependent fashion. After a once daily dosing of 8 mg Candesartan celexetil over a one week duration the drugs pressor effect was inhibited by approximately 90% at the peak, and by 50% 24 hours later (www.rxlist.com). In a 12 week study of diabetic type II p...
